{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:50:01Z","timestamp":1785199801432,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["2010"],"award-info":[{"award-number":["2010"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the phase III SPARC trial, satraplatin, an oral platinum analogue, demonstrated anticancer activity in men with metastatic castration-resistant prostate cancer (mCRPC). Repeat biopsies are uncommon in mCRPC, limiting the feasibility of tissue\u2013based biomarkers. This phase II study sought to evaluate the feasibility and utility of blood\u2013based biomarkers to identify platinum\u2013sensitive mCRPC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with mCRPC who had progressed on docetaxel were enrolled at a single center from 2011 to 2013. Subjects received satraplatin 80 mg\/m2 by mouth daily on days 1-5 and prednisone 5 mg PO twice daily, on a 35-day cycle. Serial peripheral blood samples were collected for biomarker assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen docetaxel-refractory mCRPC patients were enrolled, with a median age of 69 years (range 54-77 years) and median PSA of 71.7 ng\/mL (range 0.04-3057). Four of 13 patients (31%) responded to satraplatin (defined as a PSA decline of \u226530%). Responders demonstrated improved time to disease progression (206 vs. 35 days, HR 0.26, 95% CI, 0.02-0.24, P = .003). A 6-gene peripheral blood RNA signature and serum tissue inhibitor of metalloproteinase-1 (TIMP-1) levels were assessed as biomarkers, but neither was significantly associated with response to satraplatin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this small series, one-third of mCRPC patients responded to platinum\u2013based chemotherapy. Peripheral blood biomarker measurement is feasible in mCRPC, though the biomarkers we investigated were not associated with platinum response. Other biomarkers, such as DNA damage repair mutations, should be evaluated.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyac224","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T22:07:38Z","timestamp":1671142058000},"page":"366-e224","source":"Crossref","is-referenced-by-count":5,"title":["Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1093","volume":"28","author":[{"given":"Bobby C","family":"Liaw","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Kai","family":"Tsao","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Seng","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-1704","authenticated-orcid":false,"given":"Tomi","family":"Jun","sequence":"additional","affiliation":[{"name":"Sema4 , Stamford, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Gong","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Galsky","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5113-8147","authenticated-orcid":false,"given":"William K","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"issue":"7","key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cncr.25394","article-title":"Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration\u2013resistant prostate cancer patients","volume":"117","author":"Oh","year":"2011","journal-title":"Cancer."},{"issue":"3","key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/j.clgc.2019.03.008","article-title":"Effectiveness of platinum\u2013based chemotherapy in patients with metastatic prostate cancer: systematic review and meta-analysis","volume":"17","author":"Leal","year":"2019","journal-title":"Clin Genitourin Cancer."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cncr.28494","article-title":"Is prostate cancer changing?: evolving patterns of metastatic castration\u2013resistant prostate cancer","volume":"120","author":"Doctor","year":"2014","journal-title":"Cancer."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41391-017-0017-6","article-title":"Platinum sensitivity in metastatic prostate cancer: does histology matter?","volume":"21","author":"Humeniuk","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.","volume":"27","author":"Sternberg","year":"2009","journal-title":"J Clin Oncol."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S1470-2045(12)70263-2","article-title":"A whole-blood RNA transcript\u2013based prognostic model in men with castration\u2013resistant prostate cancer: a prospective study","volume":"13","author":"Ross","year":"2012","journal-title":"Lancet Oncol."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/jco.2015.33.7_suppl.166","article-title":"Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature.","volume":"33","author":"Liaw","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/89.17.1260","article-title":"Changing views of the role of matrix metalloproteinases in metastasis","volume":"89","author":"Chambers","year":"1997","journal-title":"J Natl Cancer Inst."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/bjc.1998.153","article-title":"Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer","volume":"77","author":"Remacle","year":"1998","journal-title":"Br J Cancer."},{"key":"2023040615580835300_","first-page":"875","article-title":"Different expression patterns of MMP-2 and MMP-9 in breast cancer","volume":"5","author":"Rha","year":"1998","journal-title":"Oncol Rep."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1083\/jcb.135.6.1669","article-title":"Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene","volume":"135","author":"Alexander","year":"1996","journal-title":"J Cell Biol."},{"key":"2023040615580835300_","first-page":"6267","article-title":"Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells","volume":"59","author":"Li","year":"1999","journal-title":"Cancer Res."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1523-1747.ep12483956","article-title":"Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases","volume":"97","author":"Bertaux","year":"1991","journal-title":"J Invest Dermatol."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.0.CO;2-G","article-title":"Mammary carcinoma cells over\u2013expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression","volume":"75","author":"Yoshiji","year":"1998","journal-title":"Int J Cancer."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1242\/jcs.115.17.3427","article-title":"Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs)","volume":"115","author":"Lafleur","year":"2002","journal-title":"J Cell Sci."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/pros.22945","article-title":"Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration\u2013resistant prostate cancer","volume":"75","author":"Gong","year":"2015","journal-title":"Prostate."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration\u2013resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med."},{"key":"2023040615580835300_","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration\u2013resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/4\/366\/49789509\/oyac224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/4\/366\/49789509\/oyac224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T21:52:52Z","timestamp":1701208372000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/4\/366\/6908995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,15]]},"published-print":{"date-parts":[[2023,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac224","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,12,15]]}}}